Kornimate/medical-research-clean huggingface dataset:
epigenetic changes in psychotherapy of adolescents with borderline personality pathology

Conditions: Borderline Personality Disorder (BPD)

Summary: the link between epigenetic changes as an effect of psychotherapy has been investigated recently. genes investigated in these studies were brain-derived neurotrophic factor (bdnf), nr3c1, fkbp51, maoa and glut1. change in methylation of these genes could be a biomolecular mechanism of psychotherapy induced changes. this study project aims at providing evidence for a biological mechanism of personality disorder interventions in adolescence by investigating the link between epigenetic changes as an effect of psychotherapy. it investigates the correlation between changes in the methylation of the fkbp5 gene and psychotherapy induced changes in symptoms and functioning.


Eligibility criteria:
inclusion criteria: * adolescents presenting 3 or more criteria for bpd in the structured clinical interview for the diagnostic and statistical manual of mental disorders (dsm-iv) axis ii personality disorders (scid-ii) exclusion criteria: * difficulties to understand or comply with instructions * psychotic disorders * pervasive developmental disorders * severe somatic or neurological disorders * severe and persistent substance addiction * elevated risk for complications related to blood sampling

Keywords: epigenetic changes psychotherapy epigenetic regulation methylation patterns change in methylation of genes fkbp5 gene
feasibility study of interval compressed regimen using four-drugs for osteosarcoma

Conditions: Osteosarcoma; Feasibility; Treatment Response; Biomarker

Summary: the aim of the study is to test the feasibility of four-drug, interval-compressed regimen in osteosarcoma. primary objective is to explore the toxicity and mortality related to treatment. secondary objectives are to examine tumor necrosis rates after neoadjuvant chemotherapy, and to evaluate the usefulness of circulating cell-free dna, survivin, or transforming growth factor-beta1 levels as well as programmed cell death ligand 1 expression in tumor specimen as a predictive or prognostic biomarker in osteosarcoma patients.

in this study, the investigators will investigate the feasibility of interval compressed regimen using four-drugs in newly-diagnosed osteosarcoma patients. four drugs will be adriamycin, high-dose methotrexate, cisplatin, ifosfamide. all these drugs will be given preoperatively in an interval-compressed schedule, but postoperatively at a regular interval. neoadjuvant therapy will be composed of two courses, and adjuvant therapy of two or three courses depending on necrosis rates following neoadjuvant therapy.

Eligibility criteria:
inclusion criteria: * newly diagnosed osteosarcoma patients under age 40 years. exclusion criteria: * patients who don't meet the organ function criteria as follows; 1. renal function : ccr or gfr or egfr ≥ 70 ml/min/1.73 m2 2. liver function : ast/alt ≤ 5 x upper limit, total bilirubin ≤ 1.5 x upper limit of normal for age 3. cardiac function : shortening fraction ≥ 24% or ejection fraction ≥ 50% (echo) 4. lung function : no dyspnea on rest, if dyspnea exists, spo2 95% or more in room air by pulse oximetry, 5. hematologic : anc ≥ 750/ul and platelet ≥ 75,000/ul

Keywords: four-drugs, interval-compression
cardio-vascular energy transfer and ventriculo-arterial coupling in heart failure

Conditions: Heart Failure, Left-sided

Summary: the goal of this pilot study is to investigate energy transfer fram the ventricle to the arteries in patients with heart failure, primary by investigating the total power.


Eligibility criteria:
inclusion criteria: acute left ventricular failure due to: * myocardial ischemia * cardiomyopathy * myocarditis sinus rhythm age \>18 years exclusion criteria: cardiogenic shock mechanical circulatory support respiratory treatment inotropic infusions tachyarrhythmias lack of capacity to consent
methylation biosignature in childhood chronic kidney disease

Conditions: Chronic Kidney Disease; Cardiovascular Disease

Summary: chronic kidney disease (ckd) and end-stage renal disease are highly prevalent in taiwan. cardiovascular disease (cvd) is the most common cause of death in children with ckd. nitric oxide (no) deficiency links ckd and cvd. asymmetric dimethylarginine (adma), a no synthase inhibitor, its level is increased in kidney disease and cardiovascular disease and serves as a methylation biomarker. in addition to adma, uremic environment, hyperhomocysteinemia (hcy) and oxidative stress may affect dna methylation. s-adenosylmethionine (sam) is an important human methyl donor. s-adenosylhomocysteine (sah) is demethylated product. methylenetetrahydrofolate reductase (mthfr), a folate metabolism enzyme can regulate methylation pathway. the investigators intend to examine whether adma, sam/sah ratio, hcy, and mthfr gene methylation can serve as biosignature to predict cvd in children with ckd children.


Eligibility criteria:
inclusion criteria: * chronic kidney disease stage 1-4 * volunteer exclusion criteria: * pregnancy * renal transplant * congenital heart disease * not able to be adherent/complaint with study procedure * not volunteer

Keywords: chronic kidney disease cardiovascular disease nitric oxide homocysteine asymmetric dimethylarginine methylation
persistent pain after cystectomy for bladder cancer

Conditions: Pain; Surgery; Post Operative Pain

Summary: this single-center, cross-sectional survey and sensory examination is conducted to determine the prevalence, sensory characteristics and risk factors of ppsp in patients who underwent cystectomy at washington university/barnes-jewish hospital between 2009 and 2015. based on data from other lower abdominal surgeries, the investigators hypothesize that 10-15% of patients undergoing cystectomy will develop ppsp.

currently, open radical cystectomy (orc) with urinary diversion is the standard treatment for patient with muscle-invasive organ-confined bladder cancer. orc involves the complete resection of local metastatic disease and reconstruction of a functional urinary tract. additionally, minimally invasive laparoscopic surgery was shown to be safe alternative to open radical cystectomy. a total of 29,719 patients underwent a form of cystectomy in the united states between 2009 and 2011. both cystectomy procedures require a midline incision on the pubic symphysis, and as with virtually any surgical incision, it produces tissue injury and inflammation, which result is acute post-operative pain. acute pain after surgery typically subsides with tissue healing; however, some patients go on to develop persistent post-surgical pain (ppsp). it is estimated that 21-52% of people who had underwent thoracotomy, 21.5-47.3% of women who had breast surgery, and 4.7%-18% of people who had underwent abdominal surgery developed ppsp. the incidence of the condition varies substantially by the type of surgical procedure, which is also an important factor affecting the mechanism of ppsp. for example, while thoracic surgeries result in predominantly neuropathic pain due to intraoperative nerve injury, in hysterectomies and knee replacement surgeries the mechanisms of ppsp seem to be predominantly inflammatory. however, no data are currently available on the prevalence or potential mechanisms of ppsp after cystectomy. understanding the prevalence, risk factors, and the potential mechanisms underlying ppsp after cystectomy will serve the basis for investigating approaches for risk stratification and prevention of ppsp in bladder cancer patients undergoing the procedure.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18; * cystectomy for bladder cancer performed at washington university/barnes-jewish hospital between jan 1, 2009 and june 30, 2015. exclusion criteria: surveys will not be sent if any of the following criteria exist: * patient is deceased or has moved out of the united states. * preoperative record indicates multiple surgeries in the abdominopelvic region.
pediatric aquatic occupational therapy for children with sensory processing challenges

Conditions: Sensory Processing Disorder; Autism Spectrum Disorder; ADHD

Summary: children with sensory processing challenges participated in an 8-week play-based aquatic program addressing goals on behavior, sensory, and participation. it is expected that after the 8-week group, the child's goals will improve demonstrating an effective intervention to address sensory difficulties.

this study examined the effectiveness of an aquatic ot program for children with sensory processing difficulties to develop water readiness skills and improve sensory, behavior, and engagement goals. six groups of children with deficits in various sensory systems participated in an 8-week aquatic group led by an occupational therapist and occupational therapy students. each week consisted of a 45-minute aquatic group with a 5 min warmup on land, 30 mins of aquatic activities addressing the sensory system of the week, and 10 mins addressing a social activity with peers. goals were developed and assessed via the goal attainment scale (gas). parents of the participants were given the sensory processing measure (spm-2) before beginning. as a result of participating in the aquatic ot intervention, percentage of goals achieved will be analyzed. it is expected that this program proves to be beneficial and therefore aquatic ot shows potential for improving sensory processing skills, behavior, and social participation with peers.

Eligibility criteria:
inclusion criteria: * participants must be ages 4-9 years old * have an identified sensory processing problem as related on the spm assessment * able to maintain head, neck, and trunk control * able to follow 1-2 step directions exclusion criteria: * participants younger than 4 years old and older than 9 years old * requires lift to get in the water * difficulty with following 1-step directions

Keywords: aquatic therapy children sensory processing challenges aquatics water learn to swim aquatic occupational therapy occupational therapy sensory processing
upright back posture device study

Conditions: Back Pain; Postural Low Back Pain; Lower Back Pain

Summary: this is a randomized controlled study to determine if patients between the ages of 18-50 years, with posture related low back pain, who use the upright device demonstrate improved pain control and self perception of posture compared to those given standard ergonomic instruction.

back pain is a common complaint among students. for many, back pain is directly related to poor posture while sitting and standing. those who spend prolonged time sitting in poor posture often develop muscular imbalances leading to tight chest muscles and weakness in back muscles. the upright system is a device which helps provide a sensory reminder to alert users when their posture is poor. the purpose of this study is to determine if patients who use the upright posture device demonstrate improved pain control and self perception of posture when compared to those given standard ergonomic instruction.

Eligibility criteria:
inclusion criteria: * postural-related back pain exclusion criteria: * a diagnosis of significant scoliosis, herniated/bulging disc, lumbar spondylolysis, radiculitis, facet arthrosis, fibromyalgia, rheumatoid arthritis, seronegative spondyloarthropathy. * neurologic deficits on exam * currently in physical therapy (pt)

Keywords: upright back posture back pain
prehospital ventilator-associated pneumonia prevention trial

Conditions: Wounds and Injuries; Respiratory Failure; Pneumonia, Ventilator-Associated

Summary: traumatic injury in rural america is a significant cause of morbidity and mortality, and the challenges of a rural trauma system can put patients at unique risk. prolonged transport times to a trauma center, stopping for care at referring hospitals, and longer exposure to care-associated factors distinguish rural patients from their urban counterparts. ventilator-associated pneumonia (vap) is a significant risk in rural patients, increasing hospital stay, healthcare costs, and even mortality in the critically injured. the investigators propose a pilot study to test the hypothesis that a single dose of oral chlorhexidine gluconate (antiseptic) for trauma patients in the prehospital environment will decrease subsequent development of early vap. chlorhexidine is currently a standard therapy in intensive care units to prevent airway colonization and subsequent development of vap. demonstrating safety and effectiveness of prehospital infection control practices could significantly improve outcomes of traumatic injury in rural america.


Eligibility criteria:
inclusion criteria: * adults (age \>= 18 years) * endotracheal intubation * transported by air ambulance * traumatic injury * interfacility transport (no flights from scene) en route to university of iowa hospitals and clinics) exclusion criteria: * known or suspected pregnancy * prisoners * patients diagnosed with pneumonia prior to transfer * known allergy to chlorhexidine gluconate * surgical airway (tracheostomy or cricothyroidotomy) * massive aspiration * anticipated nonsurvivable injury (survival projected \< 24 hours)

Keywords: chlorhexidine randomized controlled trial emergency medical services intubation, endotracheal
clinical evaluation of a covid-19 antigen self-test (covidx™)

Conditions: SARS-CoV-2; Covid19

Summary: prospective study that will evaluate the clinical agreement of the covidx™ self test compared to sars-cov-2 rt-pcr.

subjects who are currently experiencing symptoms associated with covid-19 will be enrolled. each enrolled subject will either self-collect one sample from the anterior nares or have the sample collected by another lay individual. each subject will then have a mid-turbinate nasal swab sample collected for comparator test

Eligibility criteria:
inclusion criteria: * mid-turbinate nasal swab collected for sars-cov-2 rt-pcr at the same time of covidx rapid antigen swab collection * symptomatic subjects suspected of having covid-19, first onset of covid-19-like symptoms (e.g., chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea) should not have started more than 5 days from the time of the study visit. symptoms must be present on the day of covidx testing. * ≥ 2 years of age * participants between 2-13 years of age, inclusive, must participate with a guardian who will be collecting the swab. * signed informed consent exclusion criteria: * participants with prior medical or laboratory training * unable or unwilling to provide signed, informed consent * less than 2 years of age * received a positive diagnostic test result for covid-19 in the past 14 days * received a negative diagnostic test result for covid-19 in the last 18 hours * study comparator collection that occurred \> 3 hours from covidx swab collection * for symptomatic participants: first onset of covid-19-like symptoms occurring more than 5 days from study visit * invalid or missing study comparator test results * use of a non-high-sensitive sars-cov-2 test as the comparator sars-cov-2 rt-pcr test (e.g., rapid molecular, rapid antigen tests, tests that do not have fda eua, a test that was not approved by sponsor for use in the study) * enrollment in another study involving the collection of a nasopharyngeal, mid-turbinate nasal swab or anterior nasal swab within 6 hours of covidx testing. * indicates they would not use a covid-19 diagnostic test kit in real life * taking any of the following medications or treatments within 7 days of study visit (antivirals (e.g., remdesivir, paxlovid) and/or monoclonal antibodies (e.g., regen-cov (casirivimab, imdevimab), sotrovimab (xevudy), evusheld) * nasal spray administration in the last 48 hours

Keywords: antigen rapid point of care testing self testing
safety and efficacy of env515 travoprost extended release (xr) in patients with bilateral ocular hypertension or primary open angle glaucoma

Conditions: Glaucoma and Ocular Hypertension

Summary: this is a multiple cohort study that will evaluate the safety and efficacy of env515 travoprost xr in patients with open-angle glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * diagnosis of either ocular hypertension or open angle glaucoma in both eyes. * are currently treated with topical pga for ocular hypertension in both eyes. * patients who in the opinion of the investigator: have an iop in both eyes that is considered to be adequately controlled, can be safely withdrawn from iop medications in both eyes during the washout period, and who are not considered to be at significant risk for disease progression throughout the trial. exclusion criteria: * eye surgery (including cataract surgery) within the past 3 months. * history of glaucoma related surgery.
a study to determine the efficacy and safety of finerenone and sglt2i in combination in hospitalized patients with heart failure (confirmation-hf)

Conditions: Heart Failure

Summary: combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.

this is an international, randomized, controlled, open-label, trial of an early, intensive management strategy using the combination of finerenone plus sodium-glucose co-transporter 2 inhibitor (sglt2i) compared with usual care in patients hospitalized with heart failure (hf).

Eligibility criteria:
inclusion criteria: * provide electronic or written informed consent, either personally or through a legally authorized representative, as permitted by local regulations * age ≥18 years or legal age of majority if \>18 years in the participant's country of residence * current hospitalization or recently discharged with the primary diagnosis of heart failure * heart failure signs and symptoms at the time of hospital admission * elevated n-terminal pro b-type natriuretic peptide (ntprobnp) ≥500 pg/ml or b-type natriuretic peptide (bnp) ≥125 pg/ml according to the local lab for patients in sinus rhythm; or elevated ntprobnp ≥1500 pg/ml or bnp ≥375 pg/ml for patients with atrial fibrillation (af), measured during the current hospitalization or in the 72 hours prior to hospital admission * fulfillment of protocol defined stabilization criteria (if randomized during hospitalization) * treatment during the index hospitalization with at least 1 intravenous dose of a loop diuretic (e.g., furosemide, torsemide, bumetanide). * negative pregnancy test and agreement to use adequate contraception during trial (female participants only) exclusion criteria: * diagnosis of type 1 diabetes or prior history of diabetic ketoacidosis * documented prior history of severe hyperkalemia in the setting of mra use * treatment with non-steroidal mineralocorticoid receptor antagonist (mra) or sglt2i * estimated glomerular filtration rate (egfr) \ 5.0 mmol/l * acute myocardial infarction, coronary revascularization, valve replacement/repair, or implantation of a cardiac resynchronization therapy device within 30 days * prior or planned heart transplant * hemodynamically significant uncorrected primary cardiac valvular disease as primary cause of heart failure * cardiomyopathy due to acute inflammatory heart disease, infiltrative diseases, accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes, known hypertrophic obstructive cardiomyopathy, complex congenital heart disease, or pericardial constriction * probable alternative cause of participant's heart failure symptoms * concomitant systemic therapy with potent cytochrome p450 isoenzyme 3a4 (cyp3a4) inhibitors or moderate cyp3a4 inducers, or potent cyp3a4 inducers * known hypersensitivity to the ip (active substance or excipients) * any other condition or therapy which would make the patient unsuitable for this study

Keywords: heart failure hospitalized
study on the correlation between gene mutation and tcm syndrome types in metastatic colorectal cancer

Conditions: Gene Mutation-Related Cancer; Traditional Chinese Medicine

Summary: to explore the correlation between gene mutations of metastatic colorectal cancer and tcm syndrome types based on second-generation sequencing technology.


Eligibility criteria:
inclusion criteria: 1. a clear pathological diagnosis is a patient with colorectal cancer; 2. have complete tnm staging information; 3. there is a clear diagnosis of the location and time of metastasis; 4. age ≥18 years old, ≤80 years old, male or female; 5. there is a clear time for the first treatment with chinese medicine; 6. patients who can receive long-term follow-up. - exclusion criteria: 1. patients with colorectal cancer diagnosed pathologically as adenosquamous carcinoma, squamous cell carcinoma, carcinoid, small cell carcinoma, malignant lymphoma, etc.; 2. patients with double cancer, multiple or metastatic colorectal cancer; 3. combined with severe acute and chronic diseases that may affect treatment and prognosis, such as myocardial infarction, stroke, severe renal insufficiency and mental illness;-